Many conditions beyond temporal pain show the potential for TRPA1 antagonists to reduce hyperalgesia such as rheumatoid arthritis, endometriosis, and IBD (inflammatory bowel disease) (24). This evidence concerns the gene TRPA1 and rheumatoid arthritis.